PARP3 Promotes AML Progression via Activation of PI3K/AKT/mTOR Signaling

Tingyong Cao(Lanzhou University Second Hospital), Li Zhao(First Hospital of Lanzhou University)

Cancers

September 20, 2025

10.3390/cancers17183076

Cited by 1

Related Papers

Acute myeloid leukemia (<scp>AML)</scp>‐derived mesenchymal stem cells induce chemoresistance and epithelial–mesenchymal transition‐like program in <scp>AML</scp> through <scp>IL</scp>‐6/<scp>JAK2</scp>/<scp>STAT3</scp> signaling

|Cancer Science|2023|46

Rhein exerts anti-multidrug resistance in acute myeloid leukemia via targeting FTO to inhibit AKT/mTOR

|Anti-Cancer Drugs|2024|10

The m6A modulator-mediated cytarabine sensitivity and immune cell infiltration signature in acute myeloid leukemia

|Journal of Cancer Research and Clinical Oncology|2023|6

The FTO inhibitor Rhein is a promising option for the treatment of multidrug resistance AML

|Research Square|2024|0